NYSE:RCUSBiotechs
Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives
Arcus Biosciences (RCUS) has wrapped up FY 2025 with fourth quarter revenue of US$33 million and a basic EPS loss of US$0.89, alongside a net loss of US$106 million. This sets a clear backdrop of solid top line contributions paired with continued negative earnings. The company has reported quarterly revenue of US$26 million in Q4 2024, US$28 million in Q1 2025, US$160 million in Q2 2025, US$26 million in Q3 2025 and US$33 million in Q4 2025, while EPS has remained in loss territory across...